Literature DB >> 10487555

Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma.

A Terahara1, A Niemierko, M Goitein, D Finkelstein, E Hug, N Liebsch, D O'Farrell, S Lyons, J Munzenrider.   

Abstract

PURPOSE: When irradiating a tumor that abuts or displaces any normal structures, the dose constraints to those structures (if lower than the prescribed dose) may cause dose inhomogeneity in the tumor volume at the tumor-critical structure interface. The low-dose region in the tumor volume may be one of the reasons for local failure. The aim of this study is to quantitate the effect of tumor dose inhomogeneity on local control and recurrence-free survival in patients with skull base chordoma. METHODS AND MATERIALS: 132 patients with skull base chordoma were treated with combined photon and proton irradiation between 1978 and 1993. This study reviews 115 patients whose dose-volume data and follow-up data are available. The prescribed doses ranged from 66.6 Cobalt-Gray-Equivalent (CGE) to 79.2 CGE (median of 68.9 CGE). The dose to the optic structures (optic nerves and chiasm), the brain stem surface, and the brain stem center was limited to 60, 64, and 53 CGE, respectively. We used the dose-volume histogram data derived with the three-dimensional treatment planning system to evaluate several dose-volume parameters including the Equivalent Uniform Dose (EUD). We also analyzed several other patient and treatment factors in relation to local control and recurrence-free survival.
RESULTS: Local failure developed in 42 of 115 patients, with the actuarial local control rates at 5 and 10 years being 59% and 44%. Gender was a significant predictor for local control with the prognosis in males being significantly better than that in females (P = 0.004, hazard ratio = 2.3). In a Cox univariate analysis, with stratification by gender, the significant predictors for local control (at the probability level of 0.05) were EUD, the target volume, the minimum dose, and the D5cc dose. The prescribed dose, histology, age, the maximum dose, the mean dose, the median dose, the D90% dose, and the overall treatment time were not significant factors. In a Cox multivariate analysis, the models including gender and EUD, or gender and the target volume, or gender and the minimum target dose were significant. The more biologically meaningful of these models is that of gender and EUD.
CONCLUSION: This study suggests that the probability of recurrence of skull base chordomas depends on gender, target volume, and the level of target dose inhomogeneity. EUD was shown to be a useful parameter to evaluate dose distribution for the target volume.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487555     DOI: 10.1016/s0360-3016(99)00146-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

Review 1.  Clinical evidence of particle beam therapy (proton).

Authors:  Takashi Ogino
Journal:  Int J Clin Oncol       Date:  2012-03-17       Impact factor: 3.402

Review 2.  Review of clinical experience with ion beam radiotherapy.

Authors:  A D Jensen; M W Münter; J Debus
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

3.  Proton beam radiotherapy: report of the first ten patients treated at the "Centro Nazionale di Adroterapia Oncologica (CNAO)" for skull base and spine tumours.

Authors:  Roberto Orecchia; Viviana Vitolo; Maria Rosaria Fiore; Piero Fossati; Alberto Iannalfi; Barbara Vischioni; Anurita Srivastava; Jeffrey Tuan; Mario Ciocca; Silvia Molinelli; Alfredo Mirandola; Gloria Vilches; Andrea Mairani; Barbara Tagaste; Marco Riboldi; Giulia Fontana; Guido Baroni; Sandro Rossi; Marco Krengli
Journal:  Radiol Med       Date:  2013-12-12       Impact factor: 3.469

4.  Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers.

Authors:  Wei Liu; Radhe Mohan; Peter Park; Zhong Liu; Heng Li; Xiaoqiang Li; Yupeng Li; Richard Wu; Narayan Sahoo; Lei Dong; X Ronald Zhu; David R Grosshans
Journal:  Pract Radiat Oncol       Date:  2014-01-14

5.  OUTCOME OF CLIVAL CHORDOMAS AFTER SKULL BASE SURGERIES WITH MEAN FOLLOW-UP OF 10 YEARS.

Authors:  Takamitsu Tamura; Taku Sato; Yugo Kishida; Masahiro Ichikawa; Keiko Oda; Eiji Ito; Tadashi Watanabe; Jun Sakuma; Kiyoshi Saito
Journal:  Fukushima J Med Sci       Date:  2015-09-11

6.  New strategies in radiation therapy: exploiting the full potential of protons.

Authors:  Radhe Mohan; Anita Mahajan; Bruce D Minsky
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

7.  Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base.

Authors:  Hiroshi Fuji; Yoko Nakasu; Yuji Ishida; Satoshi Horiguchi; Koichi Mitsuya; Hiroya Kashiwagi; Shigeyuki Murayama
Journal:  Skull Base       Date:  2011-05

8.  Carbon ion radiotherapy for skull base chordoma.

Authors:  Jun-Etsu Mizoe; Azusa Hasegawa; Ryo Takagi; Hiroki Bessho; Takeshi Onda; Hirohiko Tsujii
Journal:  Skull Base       Date:  2009-05

9.  Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.

Authors:  Alberto Iannalfi; Emma D'Ippolito; Giulia Riva; Silvia Molinelli; Sara Gandini; Gisela Viselner; Maria Rosaria Fiore; Barbara Vischioni; Viviana Vitolo; Maria Bonora; Sara Ronchi; Rachele Petrucci; Amelia Barcellini; Alfredo Mirandola; Stefania Russo; Alessandro Vai; Edoardo Mastella; Giuseppe Magro; Davide Maestri; Mario Ciocca; Lorenzo Preda; Francesca Valvo; Roberto Orecchia
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 10.  Proton therapy in chordoma of the base of the skull: a systematic review.

Authors:  Maurizio Amichetti; Marco Cianchetti; Dante Amelio; Riccardo Maurizi Enrici; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2009-03-25       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.